Sobi has announced that the National Institute for Health and Care Excellence (NICE) has issued the Final Appraisal Document in England and Wales recommending the use of Doptelet.
Also known as avatrombopag, the treatment involves adults with primary chronic immune thrombocytopenia (ITP) who are refractory to other treatments such as corticosteroids or immunoglobulins.
The appraisal follows results from a double-blind, randomised phase 3 study with open-label extension and two sequential phase 2 studies. This research investigated the safety and efficacy of avatrombopag as a therapy for adults with primary ITP…
